Mechanisms and Consequences of Defective E Prostanoid Receptor Signaling in AERD

AERD 中 E 类前列腺素受体信号传导缺陷的机制和后果

基本信息

  • 批准号:
    8915315
  • 负责人:
  • 金额:
    $ 14.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-01 至 2016-06-30
  • 项目状态:
    已结题

项目摘要

This project tests the hypotheses that deficient EP2 receptor expression and function in platelets and leukocytes alters homeostasis of the adenylyl cyclase/cyclic adenosine monophosphate (cAMP) pathway as a disease-causing mechanism in aspirin exacerbated respiratory disease (AERD). Platelets are required for granulocyte recruitment in animal models of pulmonary inflammation, binding to leukocytes via P-selectin (CD62P) and facilitating integrin avidity. When bound to neutrophils, platelets can also form leukotriene (LT)C4 (the parent of the cysteinly leukotrienes (cys-LTs)) from neutrophil-derived LTA4. We have discovered that platelets from subjects with aspirin exacerbated respiratory disease (AERD) are markedly deficient in expression of the Gs-linked EP2 receptor for PGE2 relative to platelets from normal and aspirin-tolerant asthmatic (ATA) controls. As a result, neither exogenous PGE2 nor a selective EP2 agonist can block activation of platelets from individuals with AERD in vitro, or the formation of platelet-leukocyte aggregates. Moreover, peripheral blood samples from individuals with AERD contain several fold higher frequencies of platelet-leukocyte aggregates than do samples from normal and aspirin-tolerant ATA controls, suggesting a functional result of diminished EP2 signaling in vivo that could enhance both tissue inflammation and the generation of cys-LTs. Furthermore, the defect in EP2 receptor expression extends to peripheral blood leukocytes from individuals with AERD, accompanied by concomitantly defective expression of mRNA encoding EP4 receptors; both defects are reversed by aspirin treatment. Aim 1 is to determine the consequences of defects in the function of the EP2 subtype of prostaglandin E2 receptor on platelets in the pathophysiology of AERD. Aim 2 is to determine the consequences of deficient of EP2 and EP4 receptor signaling on 5-lipoxygenase (5-LO) pathway activity in peripheral blood leukocytes and whether the deficiency is corrected by treatment with aspirin. Aim 3 is to characterize the extent of epigenetic variation in EP receptors, classical and novel CysLTRs, and associated candidate effectors in AERD.
该项目测试了血小板中缺乏EP 2受体表达和功能的假设, 白细胞改变腺苷酸环化酶/环磷酸腺苷(cAMP)途径的稳态, 阿司匹林加重呼吸道疾病(AERD)的致病机制。以下情况需要书面陈述: 肺部炎症动物模型中粒细胞的募集,通过P-选择素与白细胞结合 (CD 62 P)和促进整合素亲合力。当与中性粒细胞结合时,血小板也可形成白三烯 (LT)C4(半胱氨酰白三烯(cys-LT)的母体)来自嗜中性粒细胞衍生的LTA 4。我们有 发现阿司匹林加重呼吸道疾病(AERD)受试者的血小板显著增加, 相对于来自正常和阿司匹林耐受的血小板, 哮喘(ATA)对照。结果,外源性PGE 2和选择性EP 2激动剂都不能 在体外阻断AERD患者的血小板活化或血小板-白细胞的形成 集料.此外,来自AERD个体的外周血样品含有数倍高的 血小板-白细胞聚集体的频率高于正常和阿司匹林耐受性ATA对照样品, 这表明在体内减少EP 2信号传导的功能结果, 炎症和cys-LT的产生。此外,EP 2受体表达的缺陷延伸到 来自AERD个体的外周血白细胞,伴随有表达缺陷 的mRNA编码EP 4受体;这两个缺陷逆转阿司匹林治疗。目标1是确定 前列腺素E2受体的EP 2亚型在血小板上的功能缺陷的后果, AERD的病理生理学目的2:探讨EP 2和EP 4受体缺失对脑缺血的影响 外周血白细胞中5-脂氧合酶(5-LO)通路活性的信号传导,以及 用阿司匹林治疗可以纠正这种缺陷。目的3是表征表观遗传变异的程度, EP受体,经典和新型CysLTRs,以及AERD中的相关候选效应物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Joshua A Boyce其他文献

Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through a cysLT1/cysLT3 receptor-dependent mechanism
  • DOI:
    10.1016/s0091-6749(02)81894-2
  • 发表时间:
    2002-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Elizabeth Anne Mellor;Heather Dipeitrantonio;K Frank Austen;Joshua A Boyce
  • 通讯作者:
    Joshua A Boyce
Chemokine receptor 3 mobilizes to the surface of human mast cells in response to IgE-mediated activation and potentiates their generation of IL-13 and IL-4
  • DOI:
    10.1016/s0091-6749(02)81303-3
  • 发表时间:
    2002-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    KS Price;EA Mellor;DS Friend;N De Jesus;Joshua A Boyce
  • 通讯作者:
    Joshua A Boyce

Joshua A Boyce的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Joshua A Boyce', 18)}}的其他基金

Control of Pulmonary Inflammation by Leukotriene E4
白三烯 E4 控制肺部炎症
  • 批准号:
    10296403
  • 财政年份:
    2021
  • 资助金额:
    $ 14.81万
  • 项目类别:
Control of Pulmonary Inflammation by Leukotriene E4
白三烯 E4 控制肺部炎症
  • 批准号:
    10468771
  • 财政年份:
    2021
  • 资助金额:
    $ 14.81万
  • 项目类别:
Control of Pulmonary Inflammation by Leukotriene E4
白三烯 E4 控制肺部炎症
  • 批准号:
    10666460
  • 财政年份:
    2021
  • 资助金额:
    $ 14.81万
  • 项目类别:
Influence of NSAIDs and AERD on the expression and function of ACE2 - implications for SARS-CoV2 severity
NSAID 和 AERD 对 ACE2 表达和功能的影响 - 对 SARS-CoV2 严重程度的影响
  • 批准号:
    10197400
  • 财政年份:
    2020
  • 资助金额:
    $ 14.81万
  • 项目类别:
CysLT and P2Y Receptors in Lung Inflammation
肺部炎症中的 CysLT 和 P2Y 受体
  • 批准号:
    10321255
  • 财政年份:
    2018
  • 资助金额:
    $ 14.81万
  • 项目类别:
CysLT and P2Y Receptors in Lung Inflammation
肺部炎症中的 CysLT 和 P2Y 受体
  • 批准号:
    10083690
  • 财政年份:
    2018
  • 资助金额:
    $ 14.81万
  • 项目类别:
Eicosanoid Networks in Aspirin Hypersensitivity
阿司匹林过敏中的类二十烷酸网络
  • 批准号:
    10296672
  • 财政年份:
    2017
  • 资助金额:
    $ 14.81万
  • 项目类别:
Eicosanoid Networks in Aspirin Hypersensitivity
阿司匹林过敏中的类二十烷酸网络
  • 批准号:
    10062848
  • 财政年份:
    2017
  • 资助金额:
    $ 14.81万
  • 项目类别:
Eicosanoid Networks in Aspirin Hypersensitivity
阿司匹林过敏中的类二十烷酸网络
  • 批准号:
    10517922
  • 财政年份:
    2017
  • 资助金额:
    $ 14.81万
  • 项目类别:
Characterization of a Novel Growth and Survival Factor for Human Mast Cells
人类肥大细胞新型生长和生存因子的表征
  • 批准号:
    8977481
  • 财政年份:
    2014
  • 资助金额:
    $ 14.81万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 14.81万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 14.81万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 14.81万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 14.81万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 14.81万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 14.81万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 14.81万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 14.81万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 14.81万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 14.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了